Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE™ Platform for the treatment of drug ...

Johnson & Johnson MedTech will enter the U.S. pulsed field ablation market following an FDA green light for its Varipulse ...

The technology is integrated with company’s electroanatomical mapping system, which helps guide operators during AF ablation.

Irvine: Johnson & Johnson MedTech has announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE Platform ...

The device, Varipulse, is a pulsed field ablation system which uses small burns or freezes to cause some scarring in the ...

FDA approves Johnson & Johnson's Varipulse for targeted atrial fibrillation treatment, enhancing precision and safety ...

J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing rapid adoption.

Johnson & Johnson MedTech has received FDA approval for its device for drug-refractory paroxysmal atrial fibrillation.

The rapidly growing aging population is driving expansion in healthcare, with rising demand for treatments and chronic disease management. Companies like AbbVie (ABBV), Medtronic (MDT), and Centene ...

Johnson & Johnson MedTech announced today that the FDA approved its Varipulse pulsed field ablation (PFA) platform for ...

Irregular heart rhythms, known as fibrillation, can disrupt the heart's ability to pump blood effectively. These chaotic ...